Company intelligence / Profile preview

SURF

Palo Alto, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Surf Bio’s SnapShot platform has demonstrated, through peer-reviewed academic and in-house preclinical studies, the ability to formulate and deliver ultra-high concentration biologics (e.g., >500–600+ mg/mL) subcutaneously using standard autoinjectors—a significant advance for making infusion-only drugs accessible by patient self-injection. In vitro and in vivo data show feasibility and promising bioavailability, but no clinical trial data reported yet.

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyRare Diseases
Modalities: Monoclonal antibodyBiologicPolymer-based formulationSpray-dried microparticle
Industry: Biotech

Partnerships

Multiple leading multinational pharmaceutical companies (names not disclosed)

Beyond the preview

Go deeper on SURF.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SURF.

Explore the full profile